GlassScriptPhysician profile
Michael O Kayatta
NPI 1972893220
$60,419.64
in general payments reported to CMS, 2019-2025
27 companies · $2,905 in 2025
The $2,905 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $12K · 2021: $2,669 · 2022: $11K · 2023: $5,387 · 2024: $4,969 · 2025: $2,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,922 · Food and Beverage: $4,271 · Consulting Fee: $3,048 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,922.48 |
| Food and Beverage | $4,270.75 |
| Consulting Fee | $3,047.50 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $44,549.60 | 2019-2025 | Da Vinci Surgical System |
| Edwards Lifesciences Corporation | $4,850.05 | 2019-2025 | Mitris Resilia Mitral Valve |
| Atricure, INC. | $4,376.73 | 2019-2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System, Synergy Ablation System |
| Baxter Healthcare | $3,241.36 | 2023-2024 | Peri-Strips Dry, Floseal, Tisseel |
| Abiomed | $1,153.93 | 2020-2025 | Impella |
| Medtronic, INC. | $513.56 | 2021-2025 | Avalus, Octopus, Corevalve Evolut R |
| Abbott Laboratories | $347.08 | 2019-2022 | |
| Medtronic Vascular, INC. | $318.85 | 2019-2020 | |
| Jenavalve Technology, INC. | $191.47 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $118.11 | 2021 | |
| Davol INC. | $106.68 | 2024-2025 | Progel Applicator Spray Tips |
| Lexington Medical, INC. | $95.59 | 2025 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Coastal Medical Technologies LLC | $58.50 | 2024-2025 | |
| Bsn Medical INC | $44.07 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $41.09 | 2022 | |
| W. L. Gore & Associates, INC. | $35.96 | 2023-2024 | Gore Excluder Aaa Endoprosthesis, Gore Excluder Iliac Branch Endoprosthesis |
| Zimmer Biomet Holdings, INC. | $34.55 | 2023 | Sternalock Blu System |
| Clearflow INC. | $33.65 | 2025 | Pleuraflow System With Flowglide |
| Stryker Corporation | $32.52 | 2025 | Na |
| Angiodynamics, INC. | $30.26 | 2019-2021 | |
| Lemaitre Vascular, INC. | $23.09 | 2024 | Artegraft Vascular Graft |
| Vital Connect, INC | $22.09 | 2025 | Vitalpatch Rtm |
| Ge Healthcare | $21.77 | 2021 | |
| Merck Sharp & Dohme LLC | $20.77 | 2024 | Keytruda |
| On Target Laboratories, INC | $19.57 | 2024 | Cytalux |
| Acumed LLC | $13.74 | 2024 | Biobridge, Ribloc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kayatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.